1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

TABLE 1: Demographic, clinical, treatment, and imaging data
Pt/Age, y/Sex IV tPA Initial NIHSS score Time to First MR Study, h:min Initial DWI Volume, cm³ Enhancement Pattern Contrast Agent Dose^† Follow-Up Studies^* Hemorrhage
1/57/F Yes 14 5:00 44.73 Vascular 1× MR3, CT AH
2/71/M Yes 12 4:00 62.73 Parenchymal and vascular 1× CT SH
3/66/M Yes 19 3:30 117.58 Vascular 1× MR3, CT None
4/72/F Yes 16 4:00 17.65 Vascular 1× MR3 None
5/56/M Yes 10 3:00 18.59 Parenchymal and vascular 1× MR3, CT AH
6/68/M Yes 15 5:30 28.09 Parenchymal and vascular 1× MR3, CT SH
7/63/F No 14 6:00 33.66 Vascular 2× MR3, MR7 AH
8/70/M No 16 6:30 58.07 Vascular 2× MR3, MR7 None
9/67/F No 7 5:00 16.59 Vascular 2× MR3, MR7 None
10/67/F No 5 6:00 34.6 Vascular 2× MR3, MR7 None
11/84/F No 13 5:00 8.47 Vascular 2× MR3, MR7 None
12/75/M No 5 6:30 10.79 Vascular 2× MR3, MR7 None
13/74/F No 15 3:30 13.88 Vascular 2× MR3, MR7, CT None
14/52/M No 10 5:00 35.6 Vascular 2× MR3 None
15/77/M No 16 2:00 12.92 Vascular 2× MR3, MR7, CT None
16/81/F No 17 3:00 84.81 Vascular 1× MR3, MR7 None
17/78/F No 5 5:00 16.52 Vascular 2× MR3, MR7 None
18/55/M No 21 6:00 65.07 Vascular 2× MR3, MR7 AH
19/77/M No 7 6:30 2.3 Vascular 2× MR3, MR7 AH
20/46/F No 14 6:30 12.41 Vascular 2× MR3, MR7 None
21/57/M No 16 7:00 72.65 Vascular 2× MR3, MR7 AH
22/78/M No 20 3:30 90.43 Vascular 2× MR3, MR7 AH
* MR3 indicates MR imaging at day 3; MR7, MR imaging at day 7.
† Gadopentetate dimeglumine dose, 0.1 mmol/kg (= 1×) or 0.2 mmol/kg (= 2×).